STOCK TITAN

111, Inc. Regains Compliance with NASDAQ Requirement

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

111, Inc. (NASDAQ: YI) has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq on February 10, 2025, that its American Depositary Shares maintained a closing bid price of $1.00 or higher for ten consecutive business days from January 24 to February 7, 2025, meeting Listing Rule 5450(a)(1) requirements. Nasdaq has officially closed this matter.

The company, which operates as a tech-enabled healthcare platform in China focusing on digitally empowering the healthcare industry's value chain, had previously faced listing compliance issues. This announcement confirms their successful resolution of the minimum bid price requirement.

111, Inc. (NASDAQ: YI) ha ripristinato con successo il rispetto dei requisiti di quotazione di Nasdaq. L'azienda ha ricevuto conferma da Nasdaq il 10 febbraio 2025, che le sue Azioni di Deposito Americano hanno mantenuto un prezzo di chiusura di offerta di $1,00 o superiore per dieci giorni lavorativi consecutivi dal 24 gennaio al 7 febbraio 2025, soddisfacendo i requisiti della Regola di Quotazione 5450(a)(1). Nasdaq ha ufficialmente chiuso questa questione.

L'azienda, che opera come una piattaforma sanitaria abilitata dalla tecnologia in Cina, concentrandosi sul potenziamento digitale della catena del valore dell'industria sanitaria, aveva precedentemente affrontato problemi di conformità per la quotazione. Questo annuncio conferma la loro risoluzione riuscita del requisito del prezzo minimo di offerta.

111, Inc. (NASDAQ: YI) ha recuperado con éxito el cumplimiento de los requisitos de cotización de Nasdaq. La empresa recibió confirmación de Nasdaq el 10 de febrero de 2025, que sus Acciones de Depósito Americano mantuvieron un precio de oferta de cierre de $1.00 o más durante diez días hábiles consecutivos del 24 de enero al 7 de febrero de 2025, cumpliendo con los requisitos de la Regla de Cotización 5450(a)(1). Nasdaq ha cerrado oficialmente este asunto.

La compañía, que opera como una plataforma de salud habilitada por tecnología en China, centrada en empoderar digitalmente la cadena de valor de la industria de la salud, había enfrentado previamente problemas de cumplimiento de cotización. Este anuncio confirma su resolución exitosa del requisito del precio mínimo de oferta.

111, Inc. (NASDAQ: YI)는 Nasdaq의 상장 요구 사항을 성공적으로 회복하였습니다. 회사는 2025년 2월 10일 Nasdaq으로부터 2025년 1월 24일부터 2월 7일까지 10일 연속으로 미화 1.00달러 이상의 종가를 유지한 미국예탁주식에 대한 확인을 받았으며, 이는 상장 규칙 5450(a)(1)의 요구 사항을 충족합니다. Nasdaq는 이 사안을 공식적으로 종료하였습니다.

회사는 중국에서 기술 기반의 의료 플랫폼으로 운영되며, 의료 산업의 가치 사슬을 디지털 방식으로 강화하는 데 중점을 두고 있습니다. 이 회사는 과거에 상장 준수 문제가 있었습니다. 이번 발표는 최소 입찰가 요구 사항의 성공적인 해결을 확인합니다.

111, Inc. (NASDAQ: YI) a réussi à rétablir sa conformité avec les exigences de cotation du Nasdaq. La société a reçu une confirmation du Nasdaq le 10 février 2025, que ses Actions de Dépôt Américaines avaient maintenu un prix de clôture de 1,00 $ ou plus pendant dix jours ouvrables consécutifs du 24 janvier au 7 février 2025, respectant ainsi les exigences de la Règle de Cotation 5450(a)(1). Le Nasdaq a officiellement clos cette affaire.

La société, qui fonctionne comme une plateforme de santé habilitée par la technologie en Chine et qui se concentre sur l'autonomisation numérique de la chaîne de valeur de l'industrie de la santé, avait précédemment rencontré des problèmes de conformité à la cotation. Cette annonce confirme la résolution réussie de l'exigence de prix d'offre minimum.

111, Inc. (NASDAQ: YI) hat erfolgreich die Einhaltung der Zulassungsanforderungen von Nasdaq wiederhergestellt. Das Unternehmen erhielt am 10. Februar 2025 die Bestätigung von Nasdaq, dass seine American Depositary Shares über einen Zeitraum von zehn aufeinanderfolgenden Geschäftstagen vom 24. Januar bis zum 7. Februar 2025 einen Schlusskurs von 1,00 USD oder höher gehalten haben, was die Anforderungen der Listing-Regel 5450(a)(1) erfüllt. Nasdaq hat diese Angelegenheit offiziell abgeschlossen.

Das Unternehmen, das als technologiegestützte Gesundheitsplattform in China tätig ist und sich auf die digitale Stärkung der Wertschöpfungskette der Gesundheitsbranche konzentriert, hatte zuvor Probleme mit der Einhaltung der Zulassung. Diese Ankündigung bestätigt die erfolgreiche Lösung des Mindestgebotsanforderung.

Positive
  • Regained Nasdaq listing compliance, eliminating immediate delisting risk
  • Maintained share price above $1.00 for required period, showing market stability
Negative
  • Previous trading below $1.00 indicates recent financial/market challenges
  • Risk of future non-compliance remains as stated in forward-looking statements

Insights

The regaining of Nasdaq compliance marks a important turning point for 111, Inc., eliminating a significant overhang that has been weighing on investor sentiment. This development carries several important implications for investors:

Market Stability Indicators:

  • The sustained trading above $1.00 for ten consecutive sessions suggests genuine market support rather than temporary price manipulation
  • Resolution of the listing compliance issue removes a major risk factor that typically deters institutional investors
  • The company's ability to maintain listing requirements may indicate improved underlying business fundamentals

Strategic Implications:

  • Maintaining Nasdaq listing preserves access to U.S. capital markets, important for future financing needs
  • Compliance recovery often leads to improved relationships with partners and suppliers who may have been concerned about the company's market status
  • The development could facilitate potential strategic initiatives or partnerships that require stable market standing

While this compliance achievement is positive, investors should note that the company still faces significant challenges in China's competitive healthcare platform market. The forward-looking statements highlight ongoing regulatory, competitive and operational risks that require continued monitoring.

SHANGHAI, Feb. 11, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a  leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced today that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") on February 10, 2025, confirming that Nasdaq has determined that for the last ten consecutive business days, from January 24, 2025 to February 7, 2025, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1). Nasdaq noted this matter is now closed.

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

For more information on 111, please visit: http://ir.111.com.cn/.

Cision View original content:https://www.prnewswire.com/news-releases/111-inc-regains-compliance-with-nasdaq-requirement-302373468.html

SOURCE 111, Inc.

FAQ

What did 111, Inc. (YI) announce regarding Nasdaq compliance on February 10, 2025?

111, Inc. announced it regained compliance with Nasdaq's Listing Rule 5450(a)(1) after maintaining a closing bid price of $1.00 or higher for ten consecutive business days from January 24 to February 7, 2025.

How long did YI stock need to trade above $1.00 to regain Nasdaq compliance?

YI stock needed to trade at or above $1.00 for ten consecutive business days, which it achieved from January 24 to February 7, 2025.

What was the minimum share price requirement for YI to maintain Nasdaq listing?

The minimum share price requirement was $1.00 per American Depositary Share to comply with Nasdaq's Listing Rule 5450(a)(1).

What are the implications of YI regaining Nasdaq compliance for investors?

Regaining compliance means YI will continue to trade on Nasdaq, eliminating immediate delisting risk and providing continued market access for investors.

111

NASDAQ:YI

YI Rankings

YI Latest News

YI Stock Data

70.24M
6.97M
16.16%
23.9%
0.04%
Medical Distribution
Healthcare
Link
China
Shanghai